Reckitt Benckiser Group PLC Directorate Change

Reckitt Benckiser Group plc (the “Company” or “Reckitt”) today announces the appointment of Harry Kirsch, current CFO of Novartis Pharma AG and Deepak Nath, current CEO of Smith+Nephew plc, to the Board as Non-Executive Directors, effective 1 April 2026. 

Harry is currently CFO of Novartis, having joined in 2003 and held a number of senior finance roles before being promoted to his current role in 2013. He is retiring in mid-March. Prior to Novartis, Harry spent 12 years at Procter & Gamble in various finance roles. He was a Non-Executive Director at GlaxoSmithKline Consumer Healthcare Holdings Ltd between 2015-2018.

Harry currently serves as a Non-Executive Director of the Novartis Venture Fund.

Harry will join the Audit Committee from May 2026.

Deepak Nath is currently CEO of Smith+Nephew plc having joined in 2022. Prior to that Deepak held senior roles at Siemens Healthineers, Abbott Laboratories Inc, Amgen Inc and McKinsey and Co Inc. 

Deepak is currently a director of MDIC and AdvaMed.

Margherita Della Valle and Mahesh Madhavan, Non-Executive Director’s, have informed the Company of their intention to retire from the Board with effect from 1 April 2026. 

Commenting on the Board changes, Sir Jeremy Darroch, Chair of the Board said: 

“I would like to thank Margherita and Mahesh for their valued contributions to the Board and respective Committee’s. We are delighted that Harry and Deepak will be joining the Reckitt Board, bringing many years of executive leadership experience of large global businesses and we welcome the value and expertise both will bring to the Board.”

The Company confirms that there is no further information to be disclosed under the requirements of Listing Rule 9.6.13R in relation to the appointments.

Contact Details:
Catheryn O’Rourke +44 (0) 1753 217 800
General Counsel & Company Secretary

Nick Ashworth +44 (0) 7408 812350
Investor Relations